REGENXBIO, Inc. (RGNX)
9.595
+0.28
(+2.95%)
USD |
NASDAQ |
Sep 02, 16:00
9.595
0.00 (0.00%)
After-Hours: 20:00
REGENXBIO Research and Development Expense (TTM) : 213.77M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 213.77M |
| March 31, 2026 | 217.03M |
| December 31, 2025 | 212.68M |
| September 30, 2025 | 203.30M |
| June 30, 2025 | 201.55M |
| March 31, 2025 | 190.78M |
| December 31, 2024 | 192.31M |
| September 30, 2024 | 197.30M |
| June 30, 2024 | 200.64M |
| March 31, 2024 | 211.27M |
| December 31, 2023 | 214.95M |
| September 30, 2023 | 221.98M |
| June 30, 2023 | 227.93M |
| March 31, 2023 | 230.85M |
| December 31, 2022 | 229.54M |
| September 30, 2022 | 216.54M |
| June 30, 2022 | 201.80M |
| March 31, 2022 | 187.12M |
| December 31, 2021 | 171.87M |
| September 30, 2021 | 171.58M |
| June 30, 2021 | 168.34M |
| March 31, 2021 | 160.64M |
| Date | Value |
|---|---|
| December 31, 2020 | 157.89M |
| September 30, 2020 | 144.70M |
| June 30, 2020 | 136.73M |
| March 31, 2020 | 130.23M |
| December 31, 2019 | 120.40M |
| September 30, 2019 | 112.84M |
| June 30, 2019 | 97.52M |
| March 31, 2019 | 89.53M |
| December 31, 2018 | 83.87M |
| September 30, 2018 | 73.71M |
| June 30, 2018 | 67.72M |
| March 31, 2018 | 60.16M |
| December 31, 2017 | 57.22M |
| September 30, 2017 | 59.11M |
| June 30, 2017 | 59.16M |
| March 31, 2017 | 55.92M |
| December 31, 2016 | 45.48M |
| September 30, 2016 | 34.24M |
| June 30, 2016 | 27.34M |
| March 31, 2016 | 20.67M |
| December 31, 2015 | 17.28M |
| September 30, 2015 | 13.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| AbbVie, Inc. | 9.714B |
| Capricor Therapeutics, Inc. | 98.66M |
| Biogen, Inc. | 1.736B |
| United Therapeutics Corp. | 551.50M |
| Ardelyx, Inc. | 83.87M |